Previous Page  7 / 10 Next Page
Information
Show Menu
Previous Page 7 / 10 Next Page
Page Background

Page 31

International Journal of Applied Science - Research and Review

ISSN 2394-9988

E u r o p e a n C o n f e r e n c e o n

Agriculture, Horticulture

& Epigenetics

F e b r u a r y 2 5 - 2 6 , 2 0 1 9

P a r i s , F r a n c e

Agriculture & Epigenetics 2019

T

argeting MYC remains a major therapeutic goal in cancer chemotherapy.

Here, we identified that proscillaridin, a cardiac glycoside approved for

heart failure treatment, targets specifically leukemic cells overexpressing MYC

at clinically relevant doses. Proscillaridin induced rapid downregulation of MYC

proteins, reduced proliferation in leukemic cell lines and in leukemic stem cell

populations. Transcriptomic profile of leukemic cells after treatment showed

a downregulation of gene sets involved in cell replication, MYC pathways

and an upregulation of genes involved in hematopoietic differentiation.

Interestingly, low dose of proscillaridin treatment induced a significant loss

of lysine acetylation on histone H3 at lysine 9, 14, 18 and 27. Acetylome

profiling uncovered that acetylation loss included also non-histone proteins

such as MYC itself, MYC target proteins, and a series of histone acetylation

regulators. Loss of acetylation resulted from the rapid downregulation of

histone acetyltransferase proteins after treatment. Overall, these results

strongly support the re-purposing of proscillaridin in MYC overexpressing

leukemia and suggest a novel strategy to target indirectly MYC by inducing

the downregulation of a series of histone acetyltransferases involved in its

stability.

Biography

Noël J-M Raynal has completed his PhD from University of

Québec and Postdoctoral studies from MD Anderson Cancer

Center and Temple University. He is the Director of an academic

laboratory at the Centre de recherche of CHU-Sainte-Justine in

Montreal affiliated with the Department of pharmacology and

physiology of the Université de Montréal. His research focuses

on epigenetic therapy of pediatric cancers.

noel.raynal@recherche-ste-justine.qc.ca

Targeting MYC overexpressing leukemia with cardiac

glycoside proscillaridin through downregulation of histone

acetyltransferases

Noël J-M Raynal

Université de Montréal, Canada

Noël J-M Raynal, Int J Appl Sci Res Rev 2019, Volume: 6

DOI: 10.21767/2394-9988-C1-008